Table 1 Patient characteristics
Chemotherapy alone n =101 (%) | Chemotherapy+ zoledronic acid n =94 (%) | |
|---|---|---|
Median age in years (IQR) | 48 (41–54) | 47 (42–57) |
T-stage (at time of randomisation) | ||
T2 | 1 (1) | 3 (3.2) |
T3 | 55 (54.5) | 54 (57.4) |
T4 | 45 (44.6) | 37 (39.4) |
Axillary lymph involvement (at time of randomisation) | ||
1–3 | 6 (5.9) | 6 (6.4) |
Unknown | 95 (94.1) | 88 (93.6) |
Menopausal status | ||
Pre | 65 (64.4) | 55 (58.5) |
Post | 28 (27.7) | 31 (33) |
Unknown | 8 (7.9) | 8 (8.5) |
ER status | ||
+ve | 65 (64.4) | 64 (68.1) |
−ve | 36 (35.6) | 30 (31.9) |
PgR status | ||
+ve | 25 (24.8) | 32 (34) |
−ve | 46 (45.5) | 33 (35.1) |
Unknown | 30 (29.7) | 29 (30.9) |
HER2 status | ||
+ve | 22 (21.8) | 14 (14.9) |
−ve | 47 (46.5) | 49 (52.1) |
Not measured | 26 (25.7) | 24 (25.5) |
Unknown | 6 (5.9) | 7 (7.4) |
Histology | ||
Ductal | 78 (77.2) | 75 (79.8) |
Lobular | 12 (11.9) | 7 (7.4) |
Other | 7 (6.9) | 10 (10.6) |
Unknown | 4 (4) | 2 (2.1) |
Median number of lymph nodes examined (IQR) | 15 (11–19) | 14 (11–19) |
Median tumour size in mm (IQR) | ||
Clinical (n=144–74%) | 70 (60–100) | 60 (40–70) |
Ultrasound (n=91–47%) | 32 (25–46) | 31 (26–40) |
Mammogram (n=67–34%) | 40 (30–60) | 35 (27–41) |
